OMONTYS PRESERVATIVE FREE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omontys Preservative Free, and when can generic versions of Omontys Preservative Free launch?
Omontys Preservative Free is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and fourteen patent family members in thirty-four countries.
The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Omontys Preservative Free
Omontys Preservative Free was eligible for patent challenges on March 27, 2016.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMONTYS PRESERVATIVE FREE?
- What are the global sales for OMONTYS PRESERVATIVE FREE?
- What is Average Wholesale Price for OMONTYS PRESERVATIVE FREE?
Summary for OMONTYS PRESERVATIVE FREE
International Patents: | 114 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
DailyMed Link: | OMONTYS PRESERVATIVE FREE at DailyMed |
![OMONTYS PRESERVATIVE FREE drug patent expirations Drug patent expirations by year for OMONTYS PRESERVATIVE FREE](/p/graph/s/t/OMONTYS_PRESERVATIVE_FREE-patent-expirations.png)
US Patents and Regulatory Information for OMONTYS PRESERVATIVE FREE
OMONTYS PRESERVATIVE FREE is protected by six US patents.
Patents protecting OMONTYS PRESERVATIVE FREE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-006 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-006 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMONTYS PRESERVATIVE FREE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-006 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-006 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-002 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-002 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMONTYS PRESERVATIVE FREE
See the table below for patents covering OMONTYS PRESERVATIVE FREE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1849141 | Spacer moiety for poly(ethylene glycol)-modified peptide- based compounds | ⤷ Sign Up |
Slovenia | 1625156 | ⤷ Sign Up | |
Georgia, Republic of | P20135981 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USAGE THEREOF | ⤷ Sign Up |
Hong Kong | 1088616 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |